Zacks: Brokerages Anticipate Danaher Corporation (DHR) Will Announce Quarterly Sales of $4.46 Billion
Equities analysts forecast that Danaher Corporation (NYSE:DHR) will report $4.46 billion in sales for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Danaher Corporation’s earnings. The highest sales estimate is $4.53 billion and the lowest is $4.39 billion. Danaher Corporation reported sales of $4.13 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 8%. The business is scheduled to issue its next quarterly earnings report on Thursday, October 19th.
On average, analysts expect that Danaher Corporation will report full year sales of $4.46 billion for the current year, with estimates ranging from $17.92 billion to $18.15 billion. For the next year, analysts forecast that the firm will report sales of $18.79 billion per share, with estimates ranging from $18.64 billion to $18.94 billion. Zacks’ sales calculations are an average based on a survey of research analysts that cover Danaher Corporation.
Danaher Corporation (NYSE:DHR) last issued its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The company had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.50 billion. During the same period in the prior year, the business earned $0.90 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis.
DHR has been the topic of several recent research reports. Deutsche Bank AG reiterated a “buy” rating and set a $97.00 target price on shares of Danaher Corporation in a report on Wednesday, June 21st. Credit Suisse Group reissued a “buy” rating and set a $93.00 price target on shares of Danaher Corporation in a research report on Wednesday, May 24th. Citigroup Inc. set a $96.00 price target on shares of Danaher Corporation and gave the company a “buy” rating in a research report on Friday, July 21st. Zacks Investment Research raised shares of Danaher Corporation from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a research report on Friday, July 28th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $95.00 price target on shares of Danaher Corporation in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Danaher Corporation presently has a consensus rating of “Buy” and an average target price of $92.72.
Danaher Corporation (NYSE:DHR) opened at 87.24 on Thursday. The company has a market capitalization of $60.60 billion, a PE ratio of 27.85 and a beta of 1.03. Danaher Corporation has a one year low of $75.71 and a one year high of $88.01. The firm’s 50-day moving average is $82.11 and its 200 day moving average is $84.15.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 29th will be given a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Thursday, September 28th. Danaher Corporation’s payout ratio is currently 17.83%.
In related news, Director Linda P. Hefner sold 10,578 shares of the stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $83.03, for a total value of $878,291.34. Following the completion of the transaction, the director now directly owns 42,151 shares of the company’s stock, valued at approximately $3,499,797.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William King sold 7,458 shares of the stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $82.97, for a total transaction of $618,790.26. Following the completion of the transaction, the insider now directly owns 18,245 shares of the company’s stock, valued at $1,513,787.65. The disclosure for this sale can be found here. Insiders sold a total of 71,496 shares of company stock valued at $5,916,223 over the last ninety days. 12.20% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in Danaher Corporation by 2,530.9% during the 1st quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock worth $3,247,398,000 after buying an additional 36,524,795 shares during the last quarter. Flossbach Von Storch AG raised its position in Danaher Corporation by 44.7% during the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after buying an additional 1,785,810 shares during the last quarter. Vanguard Group Inc. raised its position in Danaher Corporation by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock worth $3,503,962,000 after buying an additional 1,530,015 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Danaher Corporation by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares during the last quarter. Finally, Koch Industries Inc. raised its position in Danaher Corporation by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares during the last quarter. 75.75% of the stock is owned by hedge funds and other institutional investors.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.